Financial News
Unpacking Q2 Earnings: The Pennant Group (NASDAQ:PNTG) In The Context Of Other Senior Health, Home Health & Hospice Stocks
Let’s dig into the relative performance of The Pennant Group (NASDAQ: PNTG) and its peers as we unravel the now-completed Q2 senior health, home health & hospice earnings season.
The senior health, home care, and hospice care industries provide essential services to aging populations and patients with chronic or terminal conditions. These companies benefit from stable, recurring revenue driven by relationships with patients and families that can extend many months or even years. However, the labor-intensive nature of the business makes it vulnerable to rising labor costs and staffing shortages, while profitability is constrained by reimbursement rates from Medicare, Medicaid, and private insurers. Looking ahead, the industry is positioned for tailwinds from an aging population, increasing chronic disease prevalence, and a growing preference for personalized in-home care. Advancements in remote monitoring and telehealth are expected to enhance efficiency and care delivery. However, headwinds such as labor shortages, wage inflation, and regulatory uncertainty around reimbursement could pose challenges. Investments in digitization and technology-driven care will be critical for long-term success.
The 7 senior health, home health & hospice stocks we track reported a mixed Q2. As a group, revenues beat analysts’ consensus estimates by 2%.
In light of this news, share prices of the companies have held steady as they are up 4.3% on average since the latest earnings results.
The Pennant Group (NASDAQ: PNTG)
Spun off from The Ensign Group in 2019 to focus on non-skilled nursing healthcare services, Pennant Group (NASDAQ: PNTG) operates home health, hospice, and senior living facilities across 13 western and midwestern states, serving patients of all ages including seniors.
The Pennant Group reported revenues of $219.5 million, up 30.1% year on year. This print exceeded analysts’ expectations by 4.2%. Overall, it was a very strong quarter for the company with an impressive beat of analysts’ full-year EPS guidance estimates and a solid beat of analysts’ revenue estimates.
“The second quarter represents a continuation of our robust operating momentum,” said Brent Guerisoli, the Company’s Chief Executive Officer.

The Pennant Group scored the fastest revenue growth of the whole group. Unsurprisingly, the stock is up 7.8% since reporting and currently trades at $24.
Is now the time to buy The Pennant Group? Access our full analysis of the earnings results here, it’s free for active Edge members.
Best Q2: BrightSpring Health Services (NASDAQ: BTSG)
Founded in 1974, BrightSpring Health Services (NASDAQ: BTSG) offers home health care, hospice, neuro-rehabilitation, and pharmacy services.
BrightSpring Health Services reported revenues of $3.15 billion, up 29.1% year on year, outperforming analysts’ expectations by 5.2%. The business had a very strong quarter with an impressive beat of analysts’ revenue estimates and a beat of analysts’ EPS estimates.

BrightSpring Health Services achieved the biggest analyst estimates beat among its peers. The market seems happy with the results as the stock is up 30.1% since reporting. It currently trades at $26.87.
Is now the time to buy BrightSpring Health Services? Access our full analysis of the earnings results here, it’s free for active Edge members.
Weakest Q2: Chemed (NYSE: CHE)
With a unique business model combining end-of-life care and household services, Chemed (NYSE: CHE) operates two distinct businesses: VITAS, which provides hospice care for terminally ill patients, and Roto-Rooter, which offers plumbing and water restoration services.
Chemed reported revenues of $618.8 million, up 3.8% year on year, in line with analysts’ expectations. It was a softer quarter as it posted a significant miss of analysts’ EPS estimates.
As expected, the stock is down 7.8% since the results and currently trades at $430.02.
Read our full analysis of Chemed’s results here.
Brookdale (NYSE: BKD)
With a network of over 650 communities serving approximately 59,000 residents across 41 states, Brookdale Senior Living (NYSE: BKD) operates senior living communities across the United States, offering independent living, assisted living, memory care, and continuing care retirement communities.
Brookdale reported revenues of $812.9 million, up 4.6% year on year. This result lagged analysts' expectations by 0.6%. Overall, it was a softer quarter as it also produced a significant miss of analysts’ EPS and revenue estimates.
Brookdale had the weakest performance against analyst estimates among its peers. The stock is up 10.3% since reporting and currently trades at $8.59.
Read our full, actionable report on Brookdale here, it’s free for active Edge members.
Addus HomeCare (NASDAQ: ADUS)
Serving approximately 66,000 clients across 22 states with a focus on "dual eligible" Medicare and Medicaid beneficiaries, Addus HomeCare (NASDAQ: ADUS) provides in-home personal care, hospice, and home health services to elderly, chronically ill, and disabled individuals.
Addus HomeCare reported revenues of $349.4 million, up 21.8% year on year. This number topped analysts’ expectations by 0.8%. Overall, it was a satisfactory quarter as it also recorded a narrow beat of analysts’ revenue estimates.
The stock is up 5.4% since reporting and currently trades at $112.91.
Read our full, actionable report on Addus HomeCare here, it’s free for active Edge members.
Market Update
Thanks to the Fed’s rate hikes in 2022 and 2023, inflation has been on a steady path downward, easing back toward that 2% sweet spot. Fortunately (miraculously to some), all this tightening didn’t send the economy tumbling into a recession, so here we are, cautiously celebrating a soft landing. The cherry on top? Recent rate cuts (half a point in September 2024, a quarter in November) have propped up markets, especially after Trump’s November win lit a fire under major indices and sent them to all-time highs. However, there’s still plenty to ponder — tariffs, corporate tax cuts, and what 2025 might hold for the economy.
Want to invest in winners with rock-solid fundamentals? Check out our Top 5 Quality Compounder Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
More News
View MoreQuotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.